Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-label, Intra-patient Dose-escalation Study of Erlotinib in Patients With Advanced Non-small Cell Lung Cancer Who Have Failed Prior Chemotherapy

NCT00072631 is registered in ClinicalTrials.gov with OSI Pharmaceuticals as lead sponsor.

NCT NCT00072631
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00072631 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-label, Intra-patient Dose-escalation Study of Erlotinib in Patients With Advanced Non-small Cell Lung Cancer Who Have Failed Prior Chemotherapy
Lead sponsor
OSI Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
November 5, 2003
Completion date
March 14, 2007
Enrollment
43 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non small cell lung cancer, failed prior chemotherapy